Comparison of Single-Dose Plasma and Blood Concentrations of Aripiprazole, Olanzapine, Quetiapine, Paliperidone and Risperidone After Capillary and Venous Blood Sample Collection

NCT01607762 Phase 1 COMPLETED

The purpose of this study is to compare capillary (the smallest of a body's blood vessels) and venous whole blood and plasma concentrations of 5 antipsychotics after given of a single oral, immediate-release dose to healthy participants.

Details

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 1
Status	COMPLETED
Enrolment	31
Start date	2012-02
Completion	2012-10

Conditions

• Healthy

Interventions

• Aripiprazole
• Quetiapine
• Olanzapine
• Risperidone
• Paliperidone

Primary outcomes

• Aripiprazole concentration in venous and capillary plasma, venous and capillary whole blood — 16 time points over 408 hours postdose
• Quetiapine concentration in venous and capillary plasma, venous and capillary whole blood — 12 time points over 108 hours postdose
• Olanzapine concentration in venous and capillary plasma, venous and capillary whole blood — 12 time points over 108 hours postdose
• Risperidone concentration in venous and capillary plasma, venous and capillary whole blood — 12 time points over 108 hours postdose
• Paliperidone concentration in venous and capillary plasma, venous and capillary whole blood — 12 time points over 108 hours postdose
• Dehydroaripiprazole concentration in venous and capillary plasma, venous and capillary whole blood — 16 time points over 408 hours postdose

Countries

Belgium